Neurocrine Biosciences | NBIX - Beneficio Bruto En Ventas

Precio De Mercado
133.06
Cambio Diario
1.83 1.39%
Mensual
1.00%
Anual
24.83%
Q2 Expectativa
124.95




Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 12.54B 474M 2026-03
Acadia Pharmaceuticals USD 257.76M 778K 2025-12
Agios Pharmaceuticals USD 19.43M 1.34M 2026-03
ALKERMES USD 338.34M 72.51M 2025-12
Alnylam Pharmaceuticals USD 825M 4.3M 2026-03
Amgen USD 6.89B 415M 2025-12
Biogen USD 1.82B 169.5M 2026-03
BioMarin Pharmaceutical USD 713.01M 81.81M 2025-12
Cytokinetics USD 17.76M 15.82M 2025-12
Enanta Pharmaceuticals -22.29M 23.75M 2024-12
Exelixis USD 572.18M 7M 2025-12
Gilead Sciences USD 6.31B 106M 2025-12
Halozyme Therapeutics USD 281.77M 2.41M 2025-09
Incyte USD 1.17B 217.51M 2026-03
Ionis Pharmaceuticals USD 243M 48M 2026-03
Nektar Therapeutics USD 21.81M 8.06M 2025-12
Neurocrine Biosciences USD 787.9M 7M 2025-12
Pfizer USD 3.54B 7.61B 2025-09
Prothena USD 21K 2.39M 2025-12
Regeneron Pharmaceuticals USD 2.94B 363.7M 2026-03
Repligen USD 103.83M 3.32M 2025-12
Rigel Pharmaceuticals USD 28.49M 7.01M 2024-06
Sarepta Therapeutics USD 43.55M 204.36M 2025-12
Teva Pharmaceutical Industries USD 2.11B 547M 2026-03
Ultragenyx Pharmaceutical USD 178M 46.06M 2025-12
Vertex Pharmaceuticals USD 2.72B 62.4M 2025-12
Xoma 992K 846K 2024-06